NRF2/ARE Luciferase Reporter Cell Line - HEK293

Acting as a transcriptional regulator, nuclear factor erythroid 2-related factor 2 (Nrf2) is crucial in protecting cells from oxidative stress and xenobiotic damage. Particularly in drug-resistant tumors, overexpression of Nrf2 has been connected in the context of cancer to resistance to chemotherapy. Scientists have concentrated on finding tiny compounds that could control Nrf2 signaling to improve anti-cancer therapeutic effectiveness. In one such research, the standard chemotherapeutic medication cisplatin exhibited resistance to lung cancer A549 cells—which had more Nrf2 activity than HEK293 cells. Targeting Nrf2 and lowering its activity helps to magnify the cytotoxic properties of cisplatin, therefore implying a possible therapeutic approach. While curiously increasing Nrf2 activity in HEK293 cells, the chalcone derivative 4-methoxy chalcone (4-MC) was shown to be a molecule that reduces Nrf2 activity in A549 cells. This dual functionality opens avenues for both inhibiting cancer cell survival and protecting normal cells through differential modulation of Nrf2 activity.

Figure 1. The researchers treated A549 and HEK293 cells with chalcone derivatives (4-MC, HMC, NH-DHC) and used a reporter gene assay to measure Nrf2/ARE transcriptional activity, revealing how these compounds affect cellular defense mechanisms. (Lim J, et al., 2013)

Creative Biogene's NRF2/ARE Luciferase Reporter Cell Line - HEK293 is designed for similar research applications, providing a valuable platform for studying Nrf2-mediated transcriptional activity. The cell line enables precise monitoring of Nrf2 pathway modulation, making it ideal for drug screening and mechanistic studies on oxidative stress response pathways.